RNA interference efficiently targets human leukemia driven by a fusion oncogene in vivo

Leukemia

Volumn 32, Issue 1, 2018, Pages 224-228

  Jyotsana, N ^a   Sharma, A ^a   Chaturvedi, A ^a   Scherr, M ^a   Kuchenbauer, F ^b   Sajti, L ^c   Barchanski, A ^c   Lindner, R ^a   Noyan, F ^a   Suhs K W ^a   Grote Koska, D ^a   Brand, K ^a   Vornlocher, H P ^d   Stanulla, M ^a   Bornhauser, B ^e   Bourquin, J P ^a   Eder, M ^a   Thol, F ^a   Ganser, A ^a   Humphries, R K ^f,g   Ramsay, E ^h   Cullis, P ^g   Heuser, M ^a   more..

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY HOSPITAL ULM   (Germany)

^c LASER ZENTRUM HANNOVER E V   (Germany)

^d AXOLABS GMBH   (Germany)

^e UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^f BRITISH COLUMBIA CANCER AGENCY   (Canada)

^g UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^h Precision NanoSystems   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

RNA; ONCOPROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; FUSION GENE; GENE EXPRESSION; HUMAN; LETTER; LEUKEMIA; LEUKEMOGENESIS; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; RNA INTERFERENCE; TUMOR XENOGRAFT; ANIMAL; B CELL LEUKEMIA; B LYMPHOCYTE; FAMILIAL AMYLOID POLYNEUROPATHY; GENETICS; MOUSE; PATHOLOGY; PHYSIOLOGY;

AMYLOID NEUROPATHIES, FAMILIAL; ANIMALS; B-LYMPHOCYTES; HUMANS; LEUKEMIA, B-CELL; MICE; ONCOGENE PROTEINS, FUSION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RNA INTERFERENCE;

EID: 85041316325     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2017.269     Document Type: Letter

References (15)

1. Coelho T, Adams D, Silva A, Lozeron P, Hawkins PN, Mant T et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med 2013; 369: 819-829.
2. Fitzgerald K, Kallend D, Simon A. A highly durable RNAi therapeutic inhibitor of PCSK9. N Engl J Med 2017; 376: E38.
3. Rungta RL, Choi HB, Lin PJ, Ko RW, Ashby D, Nair J et al. Lipid nanoparticle delivery of siRNA to silence neuronal gene expression in the brain. Mol Ther Nucleic Acids 2013; 2: E136.
4. Mitelman F, Johansson B, Mertens F. The impact of translocations and gene fusions on cancer causation. Nat Rev Cancer 2007; 7: 233-245.
5. Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med 2015; 373: 1541-1552.
6. Howard KA, Rahbek UL, Liu X, Damgaard CK, Glud SZ, Andersen MO et al. RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. Mol Ther 2006; 14: 476-484.
7. Fleischmann KK, Pagel P, Schmid I, Roscher AA. RNAi-mediated silencing of MLLAF9 reveals leukemia-associated downstream targets and processes. Mol Cancer 2014; 13: 27.
8. Takenaka S, Naka N, Araki N, Hashimoto N, Ueda T, Yoshioka K et al. Downregulation of SS18-SSX1 expression in synovial sarcoma by small interfering RNA enhances the focal adhesion pathway and inhibits anchorage-independent growth in vitro and tumor growth in vivo. Int J Oncol 2010; 36: 823-831.
9. Urbinati G, Ali HM, Rousseau Q, Chapuis H, Desmaele D, Couvreur P et al. Antineoplastic effects of siRNA against TMPRSS2-ERG junction oncogene in prostate cancer. PLoS ONE 2015; 10: E0125277.
10. Koldehoff M, Steckel NK, Beelen DW, Elmaagacli AH. Therapeutic application of small interfering RNA directed against bcr-abl transcripts to a patient with imatinib-resistant chronic myeloid leukaemia. Clin Exp Med 2007; 7: 47-55.
11. Heim SMF. Cancer Cytogenetics: Chromosomal and Molecular Genetic Aberrations of Tumor Cells, 4th edn. Wiley-Blackwell, 2015.
12. Felice MS, Gallego MS, Alonso CN, Alfaro EM, Guitter MR, Bernasconi AR et al. Prognostic impact of t(1;19)/TCF3-PBX1 in childhood acute lymphoblastic leukemia in the context of Berlin-Frankfurt-Munster-based protocols. Leuk Lymphoma 2011; 52: 1215-1221.
13. Fischer U, Forster M, Rinaldi A, Risch T, Sungalee S, Warnatz HJ et al. Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options. Nat Genet 2015; 47: 1020-1029.
14. Weinstein S, Toker IA, Emmanuel R, Ramishetti S, Hazan-Halevy I, Rosenblum D et al. Harnessing RNAi-based nanomedicines for therapeutic gene silencing in B-cell malignancies. Proc Natl Acad Sci USA 2016; 113: E16-E22.
15. Jin SE, Jin HE, Hong SS. Targeted delivery system of nanobiomaterials in anticancer therapy: From cells to clinics. Biomed Res Int 2014; 2014: 814208.